Skip to main content
Premium Trial:

Request an Annual Quote

Roche Extends Cancer Screening Project with Epigenomics

NEW YORK, March 23 (GenomeWeb News) - Epigenomics and Roche Molecular Diagnostics have extended by 18 months their collaboration on cancer screening products, the companies said yesterday in a statement.


Roche has agreed to extend a license it took from Epigenomics in December on a panel of markers for colorectal cancer screening, and it will continue working on the validation of breast and prostate screening products, the companies said.


Under the terms of the agreement, Epigenomics will take over sensitivity validation for its screening tests for colorectal, prostate, and breast cancer, the companies said.


The colorectal cancer screening project is scheduled to continue until the end of the year, the prostate cancer screening project is scheduled to last until at least Oct. 15, and the breast cancer screening project is scheduled to last until at least March 30, 2007, the companies said.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.